Newron Pharmaceuticals Archives

Meet some of the biotechs attending Bio-Europe Spring 2023

As Bio-Europe Spring 2023 is set to take place from March 20 to March 22 in Basel, Switzerland, a budding biotech hub, the event will provide opportunities to engage with representatives of hundreds of companies from around the world. At the convention, exhibitors will be able to showcase their innovations and meet with prospective sponsors, […]

March 10, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 16 Feb 2023

Newron reports ‘striking’ schizophrenia study results

Newron Pharmaceuticals S.p.A. has announced what it says are ‘very exciting new results’ from the first 100 randomized patients who have completed one year of treatment in its study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS) not responding to their current antipsychotic medication. […]

February 16, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 6 Jan 2023

Beyond Biotech podcast 28: Mainz Biomed, Newron Pharmaceuticals

This week, we have two guests. We have conversations with Newron CEO, Stefan Weber, and Mainz Biomed CEO, Guido Bächler. Mainz Biomed year-end corporate review Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced its corporate summary for the fiscal year ended December 31, 2022. The company launched […]

January 6, 2023

News and Trends 3 Jan 2023

Newron announces interim results from treatment-resistant schizophrenia trial

Newron Pharmaceuticals S.p.A. has announced what it says are “very compelling new results” from the first 100 enrolled patients to have reached the six-month timepoint in its international study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS), who were not responding to their current […]

January 3, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 8 May 2020

Phase III Failure Sinks Drug for Rare Neurological Disorder

The Italian biotech Newron is halting the development of the experimental drug sarizotan after it failed to meet efficacy endpoints in phase III, dashing hopes for an approved drug for Rett syndrome. Expectations had been high that the oral drug might be able to treat breathing difficulties associated with the rare genetic disorder after promising […]

May 8, 2020 - 4 minutesmins - By Anita Chakraverty

neurological disorders memory blocking uk

News and Trends 7 Nov 2017

British Researchers Find Thought Police to Treat Neurological Disorders

Cambridge University scientists have identified a chemical in the brain that blocks unwanted thoughts, offering a new avenue to treat neurological disorders. Researchers at the University of Cambridge have found identified a new process in the brain’s prefrontal cortex that can block our thoughts. The research, published in Nature Communications, demonstrated that the ability to block unwanted thoughts […]

November 7, 2017 - 3 minutesmins - By Alex Dale

Best in Biotech 10 Oct 2017

Buongiorno Biotech! Top 4 Companies Making Milan Europe’s Next Biotech Hub

Italy may not be the first country that comes to mind when you think of biotech, but the sun is rising in a new dawn for Italian biotechs that are taking their respective fields by storm. Italy is home to a lot of things; food, fashion, Ferraris… but it is now quickly growing a biotech scene […]

October 10, 2017 - 7 minutesmins - By Alex Dale

News and Trends 12 May 2017

UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval

UPDATE (12/05/2017): Newron has received €11.3M as a milestone payment for the approval from its partner, Zambon, which has the rights to commercialise Xadago globally. Originally published on 21/04/2017 Newron, an Italian biotech focused on CNS diseases, is on a roll. The latest win? FDA approval of its Parkinson’s drug, Xadago. Just in time for World […]

May 12, 2017 - 2 minutesmins - By Evelyn Warner

Stefan Weber CEO Newron Pharmaceuticals Labiotech Meetup Munich

Interview 20 Apr 2017

Newron’s Journey to Launch the First Parkinson’s Drug in 11 Years

Philip talked to Stefan Weber, CEO of Newron Pharmaceuticals, in our first meetup in Munich last week. His company has launched a new drug that could offer many more benefits than current medications to patients with Parkinson’s. Stefan discussed how failure can be an important part of success and what being European means in biotech. […]

April 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Infographics 21 Feb 2017

Infographic: The Biggest Biotech Company in Each European Country

We had a look into European biotech and created a map with the biggest biotech companies in each country, according to their market cap. Biotech is one of the biggest employers in Europe, where companies of all sizes strive to bring the most innovative technology to the market. To illustrate the dynamic biotech ecosystem in […]

February 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Oct 2016

World Mental Health Day: How is Biotech Helping the Cause?

Biotech is one of the main forces driving the development of effective therapies to treat neurological and mental disorders. For World Mental Health Day yesterday, we want to share with you some of the latest technologies that address these conditions. Yesterday, October 10th, was World Mental Health Day: it is dedicated to raising awareness of neurological and mental disorders […]

October 11, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 May 2016

New Italian Drug is FDA approved for trials in Rare Neurological Disease

Newron sees its Investigational New Drug application approved by the FDA. It can now begin clinical trials for Rett Syndrome patients – a rare neurological disorder. Based near Milan (Italy), Newron is a Biopharma developing therapies for diseases of the central nervous system (CNS). Last year it raised over €23M to advance its pipeline, which features candidates […]

May 17, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Newron Pharmaceuticals

Meet some of the biotechs attending Bio-Europe Spring 2023

Newron reports ‘striking’ schizophrenia study results

Beyond Biotech podcast 28: Mainz Biomed, Newron Pharmaceuticals

Newron announces interim results from treatment-resistant schizophrenia trial

Phase III Failure Sinks Drug for Rare Neurological Disorder

British Researchers Find Thought Police to Treat Neurological Disorders

Buongiorno Biotech! Top 4 Companies Making Milan Europe’s Next Biotech Hub

UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval

Newron’s Journey to Launch the First Parkinson’s Drug in 11 Years

Infographic: The Biggest Biotech Company in Each European Country

World Mental Health Day: How is Biotech Helping the Cause?

New Italian Drug is FDA approved for trials in Rare Neurological Disease

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!